Envista (NYSE:NVST) Stock Price Expected to Rise, UBS Group Analyst Says

05 Nov 2026, 19:36 by Renee Jackson · The Cerbat Gem

Envista (NYSE:NVST – Get Free Report) had its price target boosted by stock analysts at UBS Group from $27.00 to $29.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group‘s target price would indicate a potential upside of 16.43% from the stock’s current price.

Several other equities research analysts also recently commented on NVST. Robert W. Baird downgraded shares of Envista from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $34.00 to $26.00 in a research report on Thursday, October 15th. Leerink Partners dropped their price target on shares of Envista from $35.00 to $32.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on Envista in a research note on Thursday, September 3rd. Piper Sandler decreased their price objective on Envista from $28.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Finally, Mizuho set a $29.00 price objective on Envista in a research note on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, Envista currently has a consensus rating of “Hold” and an average price target of $29.00.

Get Our Latest Research Report on Envista

Envista Trading Down 8.4%

NYSE NVST traded down $2.28 on Thursday, hitting $24.91. The company’s stock had a trading volume of 5,487,971 shares, compared to its average volume of 2,957,959. The firm has a market cap of $4.00 billion, a PE ratio of 42.94, a PEG ratio of 1.26 and a beta of 0.94. The company’s 50-day moving average is $24.49 and its 200 day moving average is $25.74. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. Envista has a 1-year low of $18.77 and a 1-year high of $30.42.

Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm had revenue of $691.50 million for the quarter, compared to analyst estimates of $688.74 million. During the same period last year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, analysts predict that Envista will post 1.53 earnings per share for the current fiscal year.

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares in the company, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.99% of the company’s stock.

Hedge Funds Weigh In On Envista

A number of hedge funds and other institutional investors have recently modified their holdings of NVST. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Envista in the second quarter valued at approximately $25,000. Provenance Wealth Advisors LLC bought a new position in Envista in the 3rd quarter valued at $28,000. Nisa Investment Advisors LLC grew its stake in Envista by 116.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,679 shares of the company’s stock valued at $39,000 after purchasing an additional 903 shares during the period. Nykredit A S purchased a new stake in shares of Envista during the 2nd quarter valued at $52,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in shares of Envista during the 2nd quarter valued at $63,000.

Envista News Roundup

Here are the key news stories impacting Envista this week:

Positive Sentiment: Q3 results topped estimates: Envista earned $0.40 per share, ahead of analyst expectations of $0.35–$0.36, on revenue of $691.5 million versus estimates of about $688.7 million. Revenue grew 3.2% year over year, and EPS increased from $0.32 a year earlier. Article: Envista Tops Q3 Earnings and Revenue Estimates
Positive Sentiment: Raised 2026 outlook: Management lifted its 2026 earnings guidance, citing pricing and productivity gains. Better near-term expectations may support investor sentiment. Article: Envista Q3 Earnings Call Highlights
Neutral Sentiment: Valuation views point to potential upside: One analysis describes NVST as about 8% undervalued based on earnings guidance, while a separate report cites an average analyst target price of $28.86. These are estimates, not guarantees. Article: Envista Could Be 8% Undervalued Article: Average Target Price
Negative Sentiment: China presents a margin risk: Procurement reforms in China could pressure margins as Envista moves into 2027, tempering the positive impact of the higher 2026 outlook. Article: Envista Q3 Earnings Call Highlights

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.